Upsher-Smith will focus on up-to-date packaging, serialization capabilities, and supporting contract manufacturing for third parties at its new manufacturing plant in Maple Grove, MN. The company will use its relationships with distributors and demonstrated track record in several key areas, such as FDA compliance and inspection history, Environmental Health & Safety performance, and customer service.
“Upsher-Smith is a trusted partner in health with a 104-year history of manufacturing excellence,” said Rich Fisher, president and COO, Upsher-Smith. "The opening of this world-class facility marks another important milestone for our company. We plan to use this innovative asset to support our own organic production and pipeline as well as partners looking for end-to-end supply chain solutions in the contract manufacturing space."
Upsher-Smith's offerings include environmentally sustainable solvent and aqueous-based oral solid dosage (OSD) manufacturing in tablet or capsule form, powders, liquids, and suspensions. Serialized packaging solutions include OSD/liquid bottles, unit dose blisters and liquid cups, and powder filling in sachets, bottles, and cans. Outbound packaging configurations are also aggregated in accordance with the pending Drug Supply Chain Security Act (DSCSA) conformance standards.
Upsher-Smith also manufactures small, commercial batches of products destined for FDA submissions and clinical purposes in a nearby Pilot Plant, known as Plant B. As well, the company carries processing equipment and performs analytics.
Upsher-Smith's contract manufacturing and corporate development teams will be available to meet with potential partners and answer questions during the Association for Accessible Medicines (AAM) Annual Meeting, February 13-16 in Orlando, FL, and the Drug, Chemical & Associated Technologies Association (DCAT) Week, March 20-23 in New York, NY.
